ScholarIQanswers from OpenAlex

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

PaperCitations, authors & open-access status

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study have?

ScholarIQcitation count

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study has 1,001 citations in the OpenAlex counts ScholarIQ stores.

When was Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study published?

ScholarIQyear

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study has 2018 year in the ScholarIQ index.

What is the open-access status of Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study?

ScholarIQoa status

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study has closed oa status in the ScholarIQ index.

What is the DOI of Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study?

ScholarIQdoi

The DOI for Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study is on the source record.

What is the PMID of Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study?

ScholarIQpmid

The PMID for Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study is on the source record.

What is the OpenAlex record for Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study?

ScholarIQopenalex

The OpenAlex for Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial